Interpace Biosciences Reports Strong Q4 Thyroid Growth, Debt Payoff, and Significant Balance Sheet Improvement
IDXG has more than doubled off its 52-week low of $0.443.
Summary
Interpace Biosciences reported strong growth in its core thyroid diagnostics business, eliminated all debt, and significantly improved its balance sheet, despite a GAAP revenue decline attributed to a strategic business exit.
Key Events · Earnings and Guidance · IDXG
-
Strong Thyroid Segment Growth
The company's core thyroid diagnostics business saw Q4 2025 revenue increase by 14% year-over-year and full-year 2025 revenue increase by 21% year-over-year on a pro forma basis, following the discontinuation of PancraGEN.
-
Debt Elimination
Interpace Biosciences fully paid off all outstanding debt in the fourth quarter of 2025, significantly strengthening its financial position.
-
Balance Sheet Transformation
The company's balance sheet improved dramatically, moving from a stockholders' deficit to positive equity of $22.363 million as of December 31, 2025.
-
Non-Cash Tax Benefit Boosts Net Income
Q4 2025 income from continuing operations of $22.8 million and full-year income of $25.0 million were largely due to a one-time, non-cash tax-related accounting adjustment from the release of a deferred tax valuation allowance.
Analysis · IDXG · Industrial Applications And Services
Interpace Biosciences announced its Q4 and full-year 2025 results, highlighting a successful strategic transition to a thyroid-only diagnostics company. While GAAP revenue declined due to the discontinuation of PancraGEN, the core thyroid segment demonstrated robust growth, with Q4 revenue up 14% year-over-year and full-year revenue up 21% year-over-year on a pro forma basis. Critically, the company fully paid off its debt in Q4 2025 and significantly improved its balance sheet, moving from a stockholders' deficit to positive equity of $22.363 million. This substantial de-risking and focus on a growing core business are highly positive signals for investors. The reported high net income for the quarter and year was primarily driven by a one-time, non-cash tax-related accounting adjustment, which should be noted as non-operational.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXG was trading at $1.85 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $52.4M. The 52-week trading range was $0.44 to $1.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.